Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) Equity Average (2018 - 2023)

ProQR Therapeutics' Equity Average history spans 3 years, with the latest figure at $47.5 million for Q4 2023.

  • On a quarterly basis, Equity Average fell 28.85% to $47.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $47.5 million, a 28.85% decrease, with the full-year FY2025 number at $76.1 million, up 9.3% from a year prior.
  • Equity Average hit $47.5 million in Q4 2023 for ProQR Therapeutics, down from $53.4 million in the prior quarter.
  • Over the last five years, Equity Average for PRQR hit a ceiling of $146.9 million in Q3 2021 and a floor of $33.7 million in Q1 2021.
  • Historically, Equity Average has averaged $82.5 million across 3 years, with a median of $68.9 million in 2022.
  • The widest YoY moves for Equity Average: up 261.15% in 2022, down 52.7% in 2022.
  • Tracing PRQR's Equity Average over 3 years: stood at $141.1 million in 2021, then plummeted by 52.7% to $66.7 million in 2022, then decreased by 28.85% to $47.5 million in 2023.
  • Business Quant data shows Equity Average for PRQR at $47.5 million in Q4 2023, $53.4 million in Q3 2023, and $59.9 million in Q2 2023.